THERATOPIX PHARMA
The KBO register records legal situation 012 for THERATOPIX PHARMA (Register: dissolution or liquidation); this is today's state according to the register itself, which carries no start date. The 2024 annual accounts show equity of €645k and a net result of €-206k.
| Equity | €645k |
| Net result | €-206k |
| Staff (FTE) | 2.8 |
| Better than sector | 60% |
Fragile profile, watch health in particular.
All 5 axes are computed from data Checked has read.
Dissolution or liquidation
The KBO register records that this company is being wound up. A twelve-month bankruptcy probability no longer says anything in that case, so we show no figure.
The full score breakdown, per-year score history and the indicative credit limit are in Kantoor S.
See plans →| Metric | This company | Sector median | Position in the sector |
|---|---|---|---|
| Solvency | 67.9% | 46.9% | |
| Net result | €-206k | €-1k | |
| Equity | €645k | €108k | |
| Gross operating margin | €-24k | €28k | |
| Total assets | €951k | €284k |
Show 14 other metrics
| Fiscal year | 2024 |
|---|---|
| Deposit | volledig |
| Revenue | €75k |
| EBITDA | €-172k |
| Net profit | €-206k |
| Cash flow | €-121k |
| Staff costs | €147k |
| Income taxes | €-5k |
| Dividends | - |
| Total assets | €951k |
| Equity | €645k |
| Debt | €305k |
| of which ≤ 1y | €218k |
| of which > 1y | €86k |
| Working capital | €173k |
| Employees (FTE) | 2.8 |
| 2024 | |
|---|---|
| Current ratio | 1.79 |
| Quick ratio | 0.96 |
| Working capital ratio | 18.2% |
| Solvency | 67.9% |
| Debt / equity | 0.47 |
| Long-term debt ratio | 0.13 |
| Interest coverage | -19.13 |
| Gross margin | -322.8% |
| Net margin | -274.9% |
| ROA | -21.6% |
| ROE | -31.8% |
| EBITDA margin | -230.2% |
| Days sales outstanding | 11d |
| Days payable outstanding | 15d |
| Inventory turnover | 1.74 |
| Days inventory (DSI) | 210d |
Full annual accounts (27 line items)
| Line item | Code | 2024 |
|---|---|---|
| Balance sheet, Assets | ||
| TOTAL ASSETS | 20/58 | €951k |
| Fixed assets | 21/28 | €559k |
| Formation expenses | 20 | €328 |
| Intangible fixed assets | 21 | €552k |
| Tangible fixed assets | 22/27 | €6k |
| Financial fixed assets | 28 | €168 |
| Current assets | 29/58 | €392k |
| Stocks & contracts in progress | 3 | €182k |
| Amounts receivable within one year | 40/41 | €45k |
| Cash & bank | 54/58 | €136k |
| Balance sheet, Equity & liabilities | ||
| TOTAL EQUITY & LIABILITIES | 10/49 | €951k |
| Equity | 10/15 | €645k |
| Contributions / capital | 10/11 | €805k |
| Accumulated profits (losses) | 14 | €-479k |
| Amounts payable | 17/49 | €305k |
| Amounts payable after one year | 17 | €86k |
| Amounts payable within one year | 42/48 | €218k |
| Trade debts payable within one year | 44 | €13k |
| Income statement | ||
| Turnover | 70 | €75k |
| Gross operating margin | 9900 | €-24k |
| Operating result | 9901 | €-257k |
| Financial income | 75 | €56k |
| Financial charges | 65 | €9k |
| Result before taxes | 9903 | €-210k |
| Income taxes | 67/77 | €-5k |
| Net result for the period | 9904 | €-206k |
| Result to be appropriated | 9905 | €-206k |
-
Current14-08-2025 → present
| NACE primary | Vervaardiging van overige farmaceutische producten(21209) |
| Legal form | Public limited company(014) |
| Incorporation | 26-11-2019 |
| Status | Active |
| Postal code | 4000 |
Parcels linked to this company through its CBE addresses (seat, establishment units, branches), cross-referenced with the cadastral parcel plan. This shows where the company operates, not a deeds register.
| Parcel (capakey) | Region | Area | Buildings | Height / fl. |
|---|---|---|---|---|
| 62002C0005/00X010 | Wallonia | 1,679 m² | - | - |
| 62803B0206/00G002 | Wallonia | 807 m² | 1 · 128 m² | 26.3 m · 6 fl. |
A single timeline of everything that happened to this company, publications, insolvency and lifecycle events, administrative changes and filed annual accounts.
We know of 4 Belgian State Gazette acts for this company. None of them has been read yet: what they contain is neither established nor disproved here.
04-12-2025 Registered office moved within LIEGE
- Rue Saint-Laurent 313, 4000 LIEGE → Rue Louvrex 55/57, 4000 LIEGE
Technical details
{
"events": [
{
"kind": "zetel_transfer",
"seat_type": "statutaire",
"new_address": {
"city": "LIEGE",
"region": null,
"street": "Rue Louvrex",
"country": "BE",
"postcode": "4000",
"box_number": null,
"street_number": "55/57"
},
"old_address": {
"city": "LIEGE",
"region": null,
"street": "Rue Saint-Laurent",
"country": "BE",
"postcode": "4000",
"box_number": null,
"street_number": "313"
},
"effective_date": "2025-10-22",
"evidence_quote": "Par jugement du 22 octobre 2025, le Tribunal de l\u0027entreprise de Li\u00E8ge - division Li\u00E8ge a homologu\u00E9 le transfert du si\u00E8ge de la soci\u00E9t\u00E9 THERATOPIX PHARMA en liquidation au cabinet du liquidateur situ\u00E9 \u00E0 4000 LIEGE, rue Louvrex, 55/57."
}
],
"schema": "v3.2",
"act_meta": {
"model_id": 36,
"extractor": "constrained-core-35b"
},
"subject_company": {
"kbo": "0738.446.251",
"name_full": "THERATOPIX PHARMA",
"legal_form": "SA"
}
}26-08-2025 Dissolution of the company
Technical details
{
"events": [
{
"date": "2025-06-23",
"kind": "ontbinding",
"liquidators": [
{
"name": "Ma\u00EEtre Roman AYDOGDU",
"role": "vereffenaar"
}
],
"evidence_quote": "L\u0027assembl\u00E9e d\u00E9cide que la soci\u00E9t\u00E9 anonyme \u003C\u003C\u003C THERATOPIX PHARMA \u00BB ayant son si\u00E8ge \u00E0 4000 Li\u00E8ge, rue Saint-Laurent 313, T.V.A. num\u00E9ro 0738.446.251 - RPM Li\u00E8ge (division Li\u00E8ge), est dissoute et entre en liquidation \u00E0 dater de ce jour."
}
],
"schema": "v3.2",
"act_meta": {
"model_id": 36,
"extractor": "constrained-core-35b"
},
"final_status": "in_vereffening",
"subject_company": {
"kbo": "0738.446.251"
}
}07-02-2023 Capital increase of €650,000 to €805,000
- €155.000 → €805.000
Technical details
{
"events": [
{
"kind": "capital_increase",
"amount": 650000.0,
"currency": "EUR",
"after_eur": 805000.0,
"delta_eur": 650000.0,
"before_eur": 155000.0,
"amount_type": "kapitaal_effectief",
"effective_date": "2023-02-01",
"evidence_quote": "L\u0027assembl\u00E9e d\u00E9cide d\u0027augmenter le capital \u00E0 concurrence de six cent cinquante mille euros (650.000,00 \u20AC) pour le porter de cent cinquante-cinq mille euros (155.000,00 \u20AC) \u00E0 huit cent cinq mille euros (805.000,00 \u20AC) par la cr\u00E9ation de 1.670 actions nouvelles sans d\u00E9signation de valeur nominale, \u00E0 souscrire en num\u00E9raire au prix de 100 \u20AC ou 428,57 \u20AC par action, et \u00E0 lib\u00E9rer imm\u00E9diatement par les souscripteurs.",
"contribution_type": "cash"
}
],
"schema": "v3.2",
"act_meta": {
"model_id": 36,
"extractor": "constrained-core-35b"
},
"subject_company": {
"kbo": "0738.446.251",
"name_full": "THERATOPIX PHARMA",
"legal_form": "SA"
}
}28-11-2019 Incorporation of a new SNC
Technical details
{
"kind": "oprichting",
"seat": "4000 Li\u00E8ge, Rue Saint-Laurent 313",
"schema": "v3.2",
"act_meta": {
"model_id": 36,
"extractor": "constrained-core-35b"
},
"founders": [
{
"org": null,
"kind": "natural_person",
"person": {
"dob": "1976-11-26",
"name": "OLIVIER Sabine Monique Paule Ghislaine",
"niss": null,
"address": "4000 Li\u00E8ge, rue Saint-Laurent, 313"
},
"share_class": "capital",
"partner_role": null,
"holder_org_kbo": null,
"holder_org_name": null,
"contribution_type": "cash",
"amount_paid_in_eur": 50000,
"holder_person_name": "OLIVIER Sabine Monique Paule Ghislaine",
"is_subscriber_only": false,
"n_shares_subscribed": 500,
"amount_subscribed_eur": 50000,
"is_anonymous_silent_partner": false
},
{
"org": null,
"kind": "natural_person",
"person": {
"dob": "1963-01-02",
"name": "BOURS Vincent Marie Henri Nicolas",
"niss": null,
"address": "4000 Li\u00E8ge, rue Saint-Laurent, 313"
},
"share_class": "capital",
"partner_role": null,
"holder_org_kbo": null,
"holder_org_name": null,
"contribution_type": "cash",
"amount_paid_in_eur": 40000,
"holder_person_name": "BOURS Vincent Marie Henri Nicolas",
"is_subscriber_only": false,
"n_shares_subscribed": 400,
"amount_subscribed_eur": 40000,
"is_anonymous_silent_partner": false
},
{
"org": {
"kbo": "0599.848.790",
"name": "PHARMBIOSOL"
},
"kind": "rechtspersoon",
"person": null,
"share_class": "capital",
"partner_role": null,
"holder_org_kbo": "0599.848.790",
"holder_org_name": "PHARMBIOSOL",
"contribution_type": "cash",
"amount_paid_in_eur": 10000,
"holder_person_name": null,
"is_subscriber_only": false,
"n_shares_subscribed": 100,
"amount_subscribed_eur": 10000,
"is_anonymous_silent_partner": false
}
],
"capital_eur": 100000,
"subject_company": {
"kbo": "0738.446.251",
"name_full": "THERATOPIX PHARMA",
"legal_form": "SNC"
},
"initial_directors": [],
"incorporation_date": "2019-11-26",
"post_incorporation_mandates": []
}| Legal nameFR | THERATOPIX PHARMA |